Genotypic drug-resistance of HIV-1 CRF01_AE in Zhejiang province, 2004-2007
10.3760/cma.j.issn.0254-6450.2009.04.017
- VernacularTitle:浙江省2004-2007年HIV-1亚型CRF01_AE流行毒株的基因型耐药分析
- Author:
Ya-Ping YAO
1
;
Ruo-Lei XIN
;
Yun XU
;
Jie-Zhe YANG
;
Zhi-Hong GUO
;
Xiao-Hong PAN
;
Jia-Feng ZHANG
;
Ling-Jie LIAO
;
Hui XING
Author Information
1. 浙江省疾病预防控制中心
- Keywords:
Human immunodeficiency virus;
Genotypic drug-resistance;
Mutation
- From:
Chinese Journal of Epidemiology
2009;30(4):376-379
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the genotypic drug-resistant mutation among treat-naive or treated patients infected with HIV-1 CRF01_AE in Zhejiang province during 2004-2007. Methods HIV-i pol amplicons (PR+RT) from 13 treated and 43 treat-naive patients were obtained by reverse transcription-polymerase chain reaction (RT-PCR). The sequences were analyzed for genotypic antiretroviral resistance through online tools (http://hivdb.stanford.edu). Results The median count of CD44+ T lymphocytes in 43treat-naive patients was 229 cells/mm3 and the median log10 viral load was 3.41. Some drug-resistant mutations were seen in these samples including amino acid 10, 46, 71, in the genes of protease (PR) and 103, 118, in the genes of reverse transcriptase (RT) whereas twenty-nine resistance mutations in the genes of PR and RT were obtained in the 13 treated patients (8/13, 61.5% ). The high prevalence of drug-resistant mutations was observed in patients who had been receiving HAART (hight active antiretroviral therapy). Among them, cross drug resistance was dominant. Correspondingly, the median counts of CD44+ T lymphocytes and the log10 viral load were 186 cells/mm3 and 3.91. Conclusion There was a low prevalence of genotypic drug-resistant mutations in treat-naive patients, but higher drug-resistant mutation in treated patients. More attention should be paid to the transmission of drug-resistant HIV strains and the antiretroviral therapy recipe should be adjusted correspondingly for the development of ART drugs, intervention as well as clinical therapy programs.
